These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36641325)

  • 1. Treatment Patterns and Outcomes in Resected Early-stage Non-small Cell Lung Cancer: An Analysis of the SEER-Medicare Data.
    West H; Hu X; Zhang S; Song Y; Chirovsky D; Gao C; Lerner A; Jiang A; Signorovitch J; Samkari A
    Clin Lung Cancer; 2023 May; 24(3):260-268. PubMed ID: 36641325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective analysis of treatment patterns, overall survival, and real-world disease-free survival in early-stage non-small cell lung cancer following complete resection.
    Hu X; Chirovsky D; Walker MS; Wang Y; Kaushiva A; Tepsick J; Samkari A
    BMC Pulm Med; 2024 Jul; 24(1):332. PubMed ID: 38987763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non-small cell lung cancer.
    West H; Hu X; Zhang S; Song Y; Chirovsky D; Gao C; Lerner A; Jiang A; Signorovitch J; Samkari A
    J Manag Care Spec Pharm; 2023 Jul; 29(7):749-757. PubMed ID: 37404067
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment Patterns and Health Resource Utilization Among Patients Diagnosed With Early Stage Resected Non-Small Cell Lung Cancer at US Community Oncology Practices.
    Buck PO; Saverno KR; Miller PJ; Arondekar B; Walker MS
    Clin Lung Cancer; 2015 Nov; 16(6):486-95. PubMed ID: 25681298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world adjuvant chemotherapy patterns and outcomes among elderly patients with resected early non-small-cell lung cancer in the USA.
    Lee JM; Wang R; Johnson A; Ogale S; Kent M; Lee JS
    Future Oncol; 2023 Jan; 19(1):37-47. PubMed ID: 36662515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
    Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
    J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non-Small-Cell Lung Cancer.
    Donington J; Hu X; Zhang S; Song Y; Arunachalam A; Chirovsky D; Gao C; Lerner A; Jiang A; Signorovitch J; Samkari A
    Clin Lung Cancer; 2024 Jul; 25(5):440-448. PubMed ID: 38627155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study.
    Chouaid C; Danson S; Andreas S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Price M; Chirila C; Hollis K; Sweeney C; Wolowacz S; Kaye JA; Kontoudis I
    Lung Cancer; 2018 Oct; 124():310-316. PubMed ID: 30119925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.
    Wang J; Wu N; Lv C; Yan S; Yang Y
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):463-469. PubMed ID: 30474757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
    Felip E; Altorki N; Zhou C; Csőszi T; Vynnychenko I; Goloborodko O; Luft A; Akopov A; Martinez-Marti A; Kenmotsu H; Chen YM; Chella A; Sugawara S; Voong D; Wu F; Yi J; Deng Y; McCleland M; Bennett E; Gitlitz B; Wakelee H;
    Lancet; 2021 Oct; 398(10308):1344-1357. PubMed ID: 34555333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term follow-up of neoadjuvant-adjuvant combination treatment of IIIA stage non-small-cell-lung cancer: results of neoadjuvant carboplatin/vinorelbine and carboplatin/paclitaxel regimens combined with selective adjuvant chemotherapy according to in-vitro chemoresistance test.
    Kolek V; Grygarkova I; Hajduch M; Klein J; Cwiertka K; Neoral C; Langova K; Mihal V
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2008 Dec; 152(2):259-66. PubMed ID: 19219217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review.
    Custodio Carretero AB; García Sáenz JA; González Larriba JL; Bobokova J; Calles Blanco A; Hernando Trancho F; García Paredes B; Rodríguez Lajusticia L; Díaz-Rubio García E
    Clin Transl Oncol; 2008 Sep; 10(9):560-71. PubMed ID: 18796373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant carboplatin-based chemotherapy in resected stage IIIA-N2 non-small cell lung cancer.
    Ou W; Sun HB; Ye X; Zhang BB; Yang H; Fang Q; Li P; Wang SY
    J Thorac Oncol; 2010 Jul; 5(7):1033-41. PubMed ID: 20502361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative adjuvant chemotherapy and radiotherapy for stage II and III non-small cell lung cancer (NSCLC).
    Lee SW; Choi EK; Chung WK; Shin KH; Ahn SD; Kim JH; Kim SW; Suh C; Lee JS; Kim WS; Kim DS; Kim DK; Park SI; Sohn KH
    Lung Cancer; 2002 Jul; 37(1):65-71. PubMed ID: 12057869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.
    Sara Kuruvilla M; Liu G; Syed I; Gwadry-Sridhar F; Sheffield BS; Sachdeva R; Pencz A; Zhan L; Hueniken K; Patel D; Balaratnam K; Khan K; Grant B; Noy S; Singh K; Liu L; Rakibuz-Zaman M; Moldaver D; Kate Shanahan M; Cheema PK
    Lung Cancer; 2022 Nov; 173():58-66. PubMed ID: 36152478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
    Chang WJ; Sun JM; Lee JY; Ahn JS; Ahn MJ; Park K
    Lung Cancer; 2014 Apr; 84(1):51-5. PubMed ID: 24521819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of adjuvant chemotherapy with carboplatin and oral S-1 for patients with completely resected stage II to IIIA non-small cell lung cancer.
    Tanaka H; Tabe C; Okumura F; Shiratori T; Ishioka Y; Itoga M; Taima K; Morimoto T; Kimura D; Tsushima T; Tasaka S
    Thorac Cancer; 2020 Jun; 11(6):1633-1638. PubMed ID: 32351044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival outcomes of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected nonsmall cell lung cancer: FAST-nab.
    Marushima H; Kimura H; Miyazawa T; Sakai H; Furuya N; Koji K; Nakamura H; Saji H
    Anticancer Drugs; 2020 Feb; 31(2):177-182. PubMed ID: 31725045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer ≥4 cm in size: an SEER-Medicare analysis.
    Malhotra J; Mhango G; Gomez JE; Smith C; Galsky MD; Strauss GM; Wisnivesky JP
    Ann Oncol; 2015 Apr; 26(4):768-773. PubMed ID: 25600562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant Chemotherapy in Resected Stage II Non-small Cell Lung Cancer: Evaluating the Impact of Dose Intensity and Time to Treatment.
    Ramsden K; Laskin J; Ho C
    Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):394-400. PubMed ID: 25800720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.